Business Description
InnoCare Pharma is a China-based drug company focused on finding and bringing to market new treatments for cancer and autoimmune conditions. Its lead product, Orelabrutinib, is an approved therapy used across a range of blood cancers and immune disorders, including various forms of lymphoma, lupus, and multiple sclerosis. The company also has a broad pipeline of additional medicines in development targeting conditions such as lung cancer, skin disorders, and other blood-related diseases. Founded in 2015 and headquartered in Beijing, InnoCare is working to expand its portfolio both within China and beyond.
